Title of the cohort

National Survey of Health and Development

Acronym for cohort


Name of Principal Investigator
First name Diana
Last nameKuh
Address of institution where award is held
InstitutionMRC Unit of Lifelong Health and Ageing
Street Address33 Bedford Place
PostcodeWC1B 5JU

United Kingdom



Contact email
Funding source

Core funding from Medical Research Council

1. The cohort includes, or expects to include, incidence of the following conditions
  • Alzheimer’s disease and other dementias
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible

Already possible

2a. Stated aim of the cohort

Now, as participants reach retirement, the research team is developing the NSHD into a life course study of ageing.

2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date


3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)

http://www.nshd.mrc.ac.uk/findings/publications.aspx http://www.nshd.mrc.ac.uk/research.aspx

3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
Age in years from:birth
To (‘until death’ if applicable):until death
4b. Study criteria: inclusion criteria

A sample of 5362 babies of all those borm in one week of March 1946

4c. Study criteria: exclusion criteria

illegimate babies

5. Size of the cohort (i.e. number of participants enrolled)

5,001 – 10,000 participants

6a. Measures used to characterise participants

Particpants have been followed up at two and four years between 6 and 31 years there were 15 follow ups research nurses visited study memebrs at 36,43,53 at 43 and 53 cognitive capability tests were included at 53 tests of physical capability were included between 47 and 54 and again at 57 women were senr questionnaires to obtain information about timing of the menopause 60-64 physical and cognitive capability and ageing of cardiovascular and musculoskeletal body systems

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)


7. Study design
  • Longitudinal
8. Cases matched by
  • Age
9a. Does the study include a specialised subset of control participants


9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date


10a. ii) Data collection end date


10a iii) Data collection for this study is
  • Data analysis ongoing
  • Closed to new patients
10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – intend to apply for funding
11. Data collected
  • Only through the study
  • Through links to medical records
  • Through links to other records or registers (such as dental records, police records etc). Please specify
  • ONS deaths and cancers, Census 1951,1971,2001
12. System in place to enable re-contact with patients for future studies
13a. Format and availability of data stored in a database
Yes/No% available
Data summarised in database yes 100
Database is web-based
Database on spreadsheet
Database is on paper
Other (specify)
Language used:
13b. Format and availability of data held as individual records
Yes/No% available
Data held as individual records
Data is web-based
Data held on computer based records yes 100
Data held on cards
Other (specify)
Language used:
14a. Are data available to other groups


14b. Access policy/mechanisms for access if data are available to other groups
  • Access Committee mechanism
15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups


16b. i) Description of available tissues/samples/DNA
  • Living donors:blood
  • Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
  • Primary Samples: Stabilised samples (frozen or fixed)
  • Secondary samples: plasma
  • Secondary samples: cell lines derived from primary samples
  • Composite samples: chip for a particular ND condition
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data


17. Is information on biological characteristics available to other groups

Yes, for all the cohort

    Types: Population Cohorts
    Member States: United Kingdom
    Diseases: Alzheimer's disease & other dementias, Neurodegenerative disease in general
    Years: N/A
    Database Categories: N/A
    Database Tags: N/A

    Export as PDF